A non-responder stopping rule was applied at 12 weeks, defined as failure to achieve 5% weight loss from baseline
PARP is another significant NAD+ consumer that becomes more active when DNA damage builds up
Statistical analysis Statistical parameters and significance are reported in the figure legends
However, constipation tends to become more common as patients progress to higher doses of GLP-1 medications
Neurological autoimmune diseases (NAD) NAD are characterized by inappropriate immune responses, including the presence of autoantibodies targeting self-antigens in the central nervous system and peripheral nervous system, leading to abnormal immune reactions and the occurrence of NAD
Among these therapies, oral semaglutide has emerged as a revolutionary advancement, offering patients the benefits of GLP-1 treatment without injections